Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD38 | P28907 | 15/20 | 0.70 |
| ▸ | KLKB1 | P03952 | 4/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28722468 | 1.00 | CD38 (0.70) | CD38KLKB1CYP3A4KCNH2MAPK14 | |
| SCHEMBL31484487 | 0.83 | CD38 (1.00) | CD38KLKB1 | |
| SCHEMBL22932801 | 0.83 | CD38 (1.00) | CD38KLKB1 | |
| SCHEMBL29696562 | 0.82 | CD38 (0.66) | CD38KLKB1CYP3A4KCNH2 | |
| SCHEMBL22932793 | 0.81 | CD38 (1.00) | CD38KLKB1 | |
| SCHEMBL29696514 | 0.81 | CD38 (1.00) | CD38KLKB1 | |
| SCHEMBL22946899 | 0.74 | CD38 (1.00) | CD38KLKB1 | |
| SCHEMBL29696427 | 0.74 | CD38 (1.00) | CD38KLKB1 | |
| SCHEMBL24094008 | 0.72 | HPGD (0.52) | CD38KLKB1MAPK14 | |
| SCHEMBL22932675 | 0.70 | CD38 (1.00) | CD38KLKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119431323-A | Heterobicyclic amides as CD38 inhibitors | 贝林格尔·英格海姆国际有限公司 | 2025-02-14 | — | — | CN | disclosed |
| CN-114423753-B | Heterobicyclic amides as CD38 inhibitors | 里邦医疗公司 | 2024-09-17 | — | — | CN | disclosed |
| EP-4003980-A1 | HETEROBICYCLIC AMIDES AS INHIBITORS OF CD38 | Ribon Therapeutics Inc. (US) | 2022-06-01 | — | — | EP | disclosed |
| CN-114423753-A | Heterobicyclic amides as CD38 inhibitors | 里邦医疗公司 | 2022-04-29 | — | — | CN | disclosed |